000 Today's Stocks

[DorseyE]

Reasons for AVNR@$56.00
Milestones for Development of Novel Therapeutics for Inflammation
w/Novartis ..................................................................... April 2005
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=9311&GoTopage=6&BzID=958....
Over 200 million in milestone payments.
Progress ..................................................... Milestones Payments
Any day now phase I ............................................. $
?????????????? phase II ............................................ $$
????????????? phase III .............................................. $$$
FDA approval ......................................................... $$$$


Milestones for Novel Reverse Cholesterol Transport Enhancing Compounds
w/AstraZeneca PLC ......................................................... July 2005
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=10424&GoTopage=4&BzID=95....
Upfront 10 million w/milestones up to 330 million
Progress ................................................... Milestones Payments
Jan 2006 phase 1 ................................................ rec'd 5 million milestone
?????????????? phase II ............................................ $$
?????????????? phase III ............................................ $$$
FDA approval......................................................... $$$$


One Self funded phase III trial
Diabetic Neuropathic Pain.................................. began June 2005
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=10106&GoTopage=5&BzID=95....

Completed NDA for involuntary emotional expression disorder, also known as pseudobulbar affect or emotional lability..... Jan 2006
(a) Avanir's Neurodex NDA accepted with priority review for Involuntary Emotional Expression Disorder..... April 2006
(b) Avanir completed the submission of its NDA to the FDA on January 27, 2006 and expects the FDA will take action on the NDA by July 30, 2006 (the "PDUFA date").
http://biz.yahoo.com/ap/060404/avanir_neurodex.html?.v=1

The Company's first commercialized product, abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=13674&GoTopage=2&BzID=95....
Further information about Avanir can be found at http://www.avanir.com/